Skip to main content

Table 2 The demographics of patients with previous DAA treatment failure and other baseline clinical characteristics

From: Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

Case Duration span (weeks) Genotype Liver cirrhosis Previous DAA treatment L31 Y93 D168 SVR 12 Discontinuation therapy Adverse events
1 8 2a       +   
2 12 1b + DCV+ASV L31 V>M>L Y93 H D168 E +   Pruritus
3 8 2a       +   Pruritus
4 8 1b    Wild Wild Wild +   
5 8 2b       +   
6 8 1b    Wild Wild Wild +   Pruritus
7 12 2a +      +   Pruritus, fatigue
8 8 2a       +   
9 8 2b       +   
10 12 1b + DCV+ASV L31 M Y93 H D168 D>E +   
11 8 1b    Wild Wild Wild +   
12 12 1b +   Wild Wild Wild + Weeks 8 (pruritus) Bloating, pruritus
13 12 1b   DCV+ASV L31 M Y93 H D168E + Weeks 6 (cellulitis) Cellulitis
14 8 1b    Wild Wild Wild +   
15 8 2a       +   Pruritus
16 8 2b       Relapse   
17 8 2a       +   Headache
18 8 1b    Wild Wild Wild +   Pruritus
  1. DCV daclatasvir, ASV asunaprevir
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us